SCHEMBL19937771

SCHEMBL19937771

Cc1c(OCCCN(C)CCN(C)C)cccc1-c1cccc(OCCCN2CCCC2)c1C

nearest known ligand 0.53

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.53
CYP2C19 P33261 1/20 0.53
CD274 Q9NZQ7 6/20 0.50
ALDH1A1 P00352 7/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HRH3 Q9Y5N1 4/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
HTT P42858 1/20 0.46
KDM4E B2RXH2 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
PKM P14618 1/20 0.46
CYP1A2 P05177 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19939389 0.89 CYP2D6 (0.52) CYP2D6CYP2C19CD274ALDH1A1SMN1; SMN2
SCHEMBL24445406 0.87 CYP2D6 (0.68) CYP2D6CYP2C19ALDH1A1SMN1; SMN2HRH3
SCHEMBL19916129 0.86 CYP2D6 (0.66) CYP2D6CYP2C19ALDH1A1SMN1; SMN2HRH3
SCHEMBL24445444 0.86 CYP2D6 (0.66) CYP2D6CYP2C19ALDH1A1SMN1; SMN2HRH3
SCHEMBL19939876 0.85 CYP2D6 (0.48) CYP2D6CYP2C19CD274ALDH1A1SMN1; SMN2
SCHEMBL19939861 0.85 CYP2D6 (0.50) CYP2D6CYP2C19CD274ALDH1A1SMN1; SMN2
SCHEMBL19937767 0.85 ALDH1A1 (0.49) CYP2D6CYP2C19CD274ALDH1A1L3MBTL1
SCHEMBL19897898 0.84 CD274 (0.49) CD274ALDH1A1HRH3KDM4E
SCHEMBL19897895 0.84 CD274 (0.49) CD274ALDH1A1HRH3KDM4E
SCHEMBL19937854 0.84 CYP2D6 (0.46) CYP2D6CYP2C19CD274ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3507284-B1 BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS BRISTOL MYERS SQUIBB CO (US) 2022-05-25 EP disclosed
WO-2018044963-A1 BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-03-08 WO disclosed